Table 4: Difficulties for the Development of Drugs that Modify the Evolution of AD

  • Scarcity of AD markers in preclinical stage
  • Scarcity of markers of AD phenotypes
  • Difficulty to obtain molecules with selective action on diseased cells
  • Most drugs will have weak effects since they act only on a part of the etiopathogenic chain
  • It is necessary to distinguish between symptomatic action and changes in the course of the disease
  • Need of a prolonged period of observation to prove delay in progression
  • Need to work with very wide human samples to achieve clinical evidence and statistical signification
  • High economic cost of trials designed to ascertain modifications in AD evolution